Effect of ivabradine, captopril and melatonin on the behaviour of rats in L-nitro-arginine methyl ester-induced hypertension
Language English Country Poland Media print
Document type Journal Article
PubMed
28195070
Knihovny.cz E-resources
- MeSH
- Antihypertensive Agents pharmacology MeSH
- Benzazepines pharmacology MeSH
- Behavior, Animal drug effects MeSH
- Hypertension drug therapy metabolism MeSH
- Angiotensin-Converting Enzyme Inhibitors pharmacology MeSH
- Ivabradine MeSH
- Captopril pharmacology MeSH
- Blood Pressure drug effects MeSH
- Rats MeSH
- Locomotion drug effects MeSH
- Melatonin pharmacology MeSH
- NG-Nitroarginine Methyl Ester metabolism MeSH
- Nitric Oxide metabolism MeSH
- Rats, Wistar MeSH
- Heart Rate drug effects MeSH
- Nitric Oxide Synthase metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Antihypertensive Agents MeSH
- Benzazepines MeSH
- Angiotensin-Converting Enzyme Inhibitors MeSH
- Ivabradine MeSH
- Captopril MeSH
- Melatonin MeSH
- NG-Nitroarginine Methyl Ester MeSH
- Nitric Oxide MeSH
- Nitric Oxide Synthase MeSH
Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h). Systolic blood pressure (SBP) and heart rate (HR) were measured by tail-cuff method once a week. The behaviour of rats was investigated during 23-hours in the phenotyper after four weeks of the treatment. Chronic administration of L-NAME induced hypertension without a change in HR. All tested substances partly prevented the increase of SBP, while ivabradine and melatonin also reduced HR. Ivabradine, captopril and melatonin reduced daily food intake, slightly decreased daily water intake and attenuated body weight gain. In L-NAME group, locomotor activity was enhanced by ivabradine, whereas exploratory behaviour was increased by melatonin and captopril. In conclusion, ivabradine, besides its potentially protective hemodynamic actions, does not seem to exert any disturbing effects on behaviour in L-NAME-induced hypertension in rats, while some of its effects were similar to captopril or melatonin. It is suggested that ivabradine used in cardiovascular indications is harmless regarding the effect on behaviour.
Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension
